Financial Headline Summary Reports
These pdf reports summarise the headline information from the Monthly Financial Headlines, Top 50 BNF Sections and Drugs and Price Concessionary bulletin reports at SICBL, ICB, regional and national level. Copies of this report are available on request via nuth.nyrdtc.rxsupp@nhs.net.
A version of the report showing the data for the 7 commissioning regions with England selected as the focus is shown below.
Time period
April to June 2026
Frequency
Monthly
Top 50 BNF sections and drugs
Overview
This report looks at the top 50 BNF sections and drugs in terms of spend at ICB and SICBL level for the financial year to date with a focus on cost growth and item growth.
Frequency
Monthly
Data period
April to June 2026
Monthly Financial Headlines
Overview
This report provides headline financial information based on total prescribing for the whole BNF at ICB, sub-ICB and PCN level for the financial year to date with particular focus on cost and item growth compared to the same period from the previous financial year plus financial forecasting.
Frequency
Monthly
Data period
June 2026
Monthly formulary amendments – June 2026
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in June 2026.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Monthly Horizon Scanning Report – June 2026
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licences, significant new guidance, and decisions that have been made by recognised bodies.
This edition covers new and updated medicines and guidance published in May 2026.
This information is produced for use by NHS healthcare professionals.
Shared care protocol – lithium in adults
This shared care protocol is based on the version published nationally by NHS England. The clinical content has been reviewed against current national guidance, and updated accordingly on the date indicated in the document.
These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.
Update information
Every effort is made to keep the content up to date. See the document control page of the template for details of any changes. These changes will be cascaded to the NEY and NW medicines committees secretariat.
Current version: v2.1
Last updated: 9th June 2026
Fezolinetant – Prescribing Information leaflet
Prescribing information leaflets have been developed to support clinicians in the prescribing of drugs classified as Green, Green (following specialist initiation) or Green (following specialist recommendation initiation) drugs on the local formularies.
These templates are provided to the North West and North East and Yorkshire ICBs for localisation and approval through standard ICB processes. Prescribers should refer to their local medicines committee website and formulary pages e.g. GMMMG, NTAG to ensure they are using the version adopted by their ICB.
Monthly formulary amendments – June 2025
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in June 2025.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Formulary assessment – Spironolactone (Qaialdo) 10 mg/1 ml oral suspension
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
The information in this document is correct at the time of publication and formulations may change. This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Formulary assessment – Pregabalin prolonged-release tablets
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.